GRAIL's Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed EndpointMarketBeat • 06/01/26
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual MeetingPRNewsWire • 05/31/26
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual MeetingPRNewsWire • 05/30/26
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual MeetingPRNewsWire • 04/21/26
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATESPRNewsWire • 04/15/26
GRAIL Partners With Epic to Broaden Galleri Test Access Across USZacks Investment Research • 04/08/26
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access NationwidePRNewsWire • 04/07/26
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 04/03/26
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early DetectionPRNewsWire • 04/01/26